FDC Limited Launches India’s First Favipiravir Oral Suspension – Favenza

• Convenient loading dosage of the oral suspension helps reduce dosage frequency 

Mumbai, 12 July 2021: Home-grown pharma major, FDC Limited, today, announced the launch of India’s first oral suspension of Favipiravir – Favenza Oral Suspension, used to treat mild to moderate cases of COVID-19. This prescription-only solution is currently available at all retail medical outlets and hospital pharmacies across the country.

The Favenza suspension is unique due to its Convenient Loading Dose (Day 1) of 18 ml in the morning and 18 ml in the evening. The results of which are equivalent to 9 tablets of Favipiravir 400mg making the process of Covid-19 treatment hassle free.

Mr. Mayank Tikkha, General Manager – Business Development & Commercial Excellence, FDC Ltd.  commented, “With positive cases on the rise again, now is the time to provide healthcare warriors in our country with viable options in this continuous battle against this disease. In order to combat Covid-19, we believe in offering best efficacy along with convenience to our patients and as such we have focused our efforts in making the process of Covid-19 treatment hassle-free.”

India, with the second highest number of cases globally, is seeing about 50,000 cases being added every day. Though on a decline, the second wave is far from over and there are fears of an oncoming third wave.